Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma

Area of Science:

• Pediatric Oncology
• Sarcoma Research
• Medical Oncology

Background:

• Metastatic Ewing sarcoma (ES) presents significant challenges with poor patient outcomes.
• Current treatment strategies for metastatic ES require optimization to improve survival rates.

Purpose of the Study:

• To evaluate the impact of intensified ifosfamide dosing on survival in patients with metastatic Ewing sarcoma.
• To assess the safety and efficacy of an escalated ifosfamide regimen in metastatic ES.

Main Methods:

• Retrospective chart review of 30 patients with metastatic ES treated with the MSKCC "EFT regimen."
• Comparison of standard ifosfamide dosing (1,800 mg/m²/day × 5 days) versus intensified dosing (2,800 mg/m²/day × 5 days).

Main Results:

• Twenty-six of 30 patients completed planned chemotherapy; two experienced disease progression.
• No toxic deaths were observed, but one patient developed secondary leukemia.
• The 4-year event-free survival (EFS) was 27%, and overall survival (OS) was 39%.

Conclusions:

• Intensified ifosfamide dosing in the EFT regimen was tolerated by patients with metastatic ES.
• The escalated ifosfamide regimen did not demonstrate improved survival outcomes for this patient group.
• Further research is needed to identify more effective treatments for metastatic Ewing sarcoma.